Dapagliflozin Reduces Hospitalizations Among Patients With CKD
TUESDAY, Dec. 6, 2022 -- For patients with chronic kidney disease (CKD), dapagliflozin reduces the risk for hospitalization, according to a study published online Dec. 6 in the Annals of Internal Medicine.
Meir Schechter, M.D., from the University...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Chronic Kidney Disease | Dapagliflozin | Forxiga | Internal Medicine | Pharmaceuticals | Study | Urology & Nephrology